Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: Cancer Discov. 2013 Dec;3(12):10.1158/2159-8290.CD-13-0775. doi: 10.1158/2159-8290.CD-13-0775

Figure 1.

Figure 1

Oncogene vs. T cell driven immune checkpoint pathway upregulation. Tumor cells can induce PD-L1 expression in a cell autonomous manner via the oncogene EGFR. Alternatively, PD-1 pathway upregulation can be the consequence of CD8 T cell infiltration. These models generate different hypotheses to identify patients who will benefit from immune checkpoint blocking therapies. Future studies may resolve the contribution of each mechanism in various malignancies.